Erika Hamilton, Chair, Executive Committee, Breast and Breast Program Lead at Sarah Cannon Research Institute, shared a post by SCRI Oncology Partners on LinkedIn, adding:
“So proud of Sarah Cannon Research Institute contributions to this important manuscript advancing Kras targeting in lung and pancreatic cancer!”
Quoting SCRI Oncology Partners‘s post:
Our own Meredith Sellers Pelster, MD, MSCI and SCRI Oncology Partners patients featured on this publication of Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer!
This is a first‑in‑class KRAS G12D degrader, showed encouraging early efficacy across difficult‑to‑treat cancers in a phase 1 study-including objective responses in 36% of patients with NSCLC and 24% of patients with pancreatic cancer, with a manageable safety profile.
Sarah Cannon Research Institute authors Alex Spira, MD, PhD, FACP, FASCO Meredith Sellers Pelster, MD, MSCI, and Judy Wang MD were proud contributors to this important study, and we’re excited to be involved in the growing number of trials targeting RAS‑driven cancers.
These advances mark a meaningful step toward changing therapy-and improving outcomes-for our patients.”
Title: Setidegrasib in Advanced Non–Small-Cell Lung Cancer and Pancreatic Cancer
Authors: Wungki Park, Anup Kasi, Alexander I. Spira, Luis Paz-Ares Rodríguez, Benjamin O. Herzberg, Meredith S. Pelster, Anthony W. Tolcher, Yasutoshi Kuboki, Shigehisa Kitano, Hirokazu Shoji, Judy S. Wang, Jordan D. Berlin, Antoine Hollebecque, Patricia LoRusso,
Christos Fountzilas, Philippe A. Cassier, Tomohiro Nishina, Daisuke Sakai, Chiaki Inagaki, Daniel Morgensztern, Makoto Ueno, Minkyu Jung, Sang-We Kim, Pasi A. Jänne, Antoine Italiano, Benoît You, T Macarulla, Hisaki Fujii, Aditya Shetty, Ying Lu, Daniel Cui, Shilpa Kadam, Stanley C. Gill, Junko Toyoshima, Takeshi Saito, Jonathan W. Goldman
Read The Full Article
Other articles about Pancreatic Cancer on OncoDaily.